Navigation Links
Stem Cell Innovations to Provide Research and Assay Services to Agennix.
Date:3/2/2010

In addition to the talactoferrin assays, SCLL will provide other research and cell culture services to Agennix.

About Agennix

Agennix AG is a publicly traded biopharmaceutical company that is developing novel therapies in areas of major unmet medical need to improve the length and quality of life of seriously ill patients.  The Company's most advanced program is talactoferrin, an oral targeted therapy that has demonstrated activity in randomized, double-blind, placebo-controlled Phase 2 studies in non-small cell lung cancer as well as in severe sepsis.  Talactoferrin is currently in Phase 3 clinical trials in non-small cell lung cancer. The Company has three sites of operation: Munich, Germany; Princeton, New Jersey and Houston, Texas. For additional information, please visit the Agennix Web site at www.agennix.com.

About Stem Cell Innovations, Inc.


'/>"/>
SOURCE Stem Cell Innovations, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Marrone Bio Innovations Announces Two New Executive Appointments
2. Inverness Medical Innovations Declares Dividend on its Series B Convertible Perpetual Preferred Stock
3. The Scientist Names Photometrics' Evolve EMCCD Camera One of the “Top 10 Innovations” of 2009
4. Marrone Bio Innovations Named an IC20 Company
5. Glycos Biotechnologies, Inc. Selected to Present at Alternative Energy Innovations 2009
6. Inverness Medical Innovations Schedules Conference Call for 10:00 a.m. ET October 27, 2009 to Discuss Third Quarter 2009 Results
7. The Growing Demand for Organic Gardening Sprouts New Self Sustaining Innovations
8. Cambrex Continuous-Flow Microwave-Assisted Organic Synthesis Technology Nominated for 2009 Innovations Award
9. Morphotek(R), Inc. and Cancer Innovations, Inc. Announce Evaluation and Option Agreement for Therapeutic Monoclonal Antibodies
10. Inverness Medical Innovations - Concateno plc, Further Announcement Regarding UK Takeover Code Share Dealing Disclosure Requirements.
11. Exosome Diagnostics and DxS Diagnostic Innovations Collaborate to Develop Blood-Based Tests for Key Cancer Mutations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... 30, 2015 AACC welcomed thousands of ... AACC Annual Meeting & Clinical Lab Expo in ... The meeting showcased revolutionary advancements in clinical testing ... healthcare providers to diagnose patients quickly and accurately ... As of Wednesday, July 29, ...
(Date:7/30/2015)... , ... July 30, 2015 , ... ... appointed Francois Vieillard as Sales & Marketing Director. , With more than ... will be responsible for reinforcing Tronics’ business development activities worldwide. He brings to ...
(Date:7/30/2015)... , July 30, 2015 According ... Product (Software, Molecular Modeling, PB/PK, PKPD, Trial Design, Toxicity ... Development, Preclinical, Clinical Trial), by End Users - Global ... is expected to reach USD 2,107.99 million by 2020 ... of 15.29%. Browse more than ...
(Date:7/30/2015)... Kan. , July 30, 2015   ... a pet therapeutics company focused on the licensing, ... companion animals, today announced that its strategic partner ... a dose confirmation study of AT-016, an adipose-derived ... for the treatment of osteoarthritis pain in dogs. ...
Breaking Biology Technology:Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 2Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 3Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 4Tronics appoints Francois Vieillard as Sales and Marketing Director 2Biosimulation Market Worth 2,107.99 Million USD by 2020 2Biosimulation Market Worth 2,107.99 Million USD by 2020 3Biosimulation Market Worth 2,107.99 Million USD by 2020 4Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 2Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 3Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 4Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 5
... 10, 2012  Spherix Incorporated (NASDAQ: SPEX ... in diabetes, metabolic syndrome and atherosclerosis, and providers ... supplement, biotechnology and pharmaceutical companies – would like ... will host a conference call to provide a ...
... Florida have developed a novel technique that may give ... pathogens associated with inflammatory bowel disease, including Crohn,s disease. ... used for detection of other microbes that have challenged ... tissue and are able to reprogram cells to successfully ...
... Syndax Pharmaceuticals, Inc. , a clinical-stage epigenetics oncology ... Texas MD Anderson Cancer Center Department of Breast ... combining Syndax,s lead product entinostat with lapatinib ditosylate ... relapsed metastatic breast cancer previously treated with trastuzumab ...
Cached Biology Technology:Reminder: Spherix to Hold Business Update Conference Call April 11 at 1:00 p.m. Eastern Time 2Reminder: Spherix to Hold Business Update Conference Call April 11 at 1:00 p.m. Eastern Time 3UCF scientists use nanotechnology to hunt for hidden pathogens 2Syndax Pharmaceuticals Announces Start of Phase 1/2 Study of Entinostat in Combination with Lapatinib in HER2-Positive Metastatic Breast Cancer 2Syndax Pharmaceuticals Announces Start of Phase 1/2 Study of Entinostat in Combination with Lapatinib in HER2-Positive Metastatic Breast Cancer 3
(Date:7/8/2015)... July 8, 2015 Summary Pancreatic cancer ... fourth most fatal, with a mortality rate of 10.9 ... of pancreatic cancer patients has highlighted a significant need ... not being met by the current market. A ... products with varying molecule types and mechanisms of action, ...
(Date:7/7/2015)... 30, 2015 Research ... addition of the "Capacitive Fingerprint Sensors Patent ... To this date, fingerprint sensing technology is the ... sensors are well developed. This patent landscape focuses ... The domain of capacitive fingerprint sensors is ...
(Date:7/2/2015)... , June 25, 2015 ... addition of the "Next Generation Biometrics Market by ... 2020" report to their offering. The ... Billion by 2020, at a CAGR of 17.9% between ... the leading application for the market. Safran SA ...
Breaking Biology News(10 mins):Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 3Worldwide Capacitive Fingerprint Sensors Patent Landscape Market Report 2015-2020 - Main IP Holders include Seiko Epson, AuthenTec, Sony and STMicroelectronics 2Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 2Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 3
... led by Lauren Cole, a public health graduate student, ... and Director of the Epidemiology Program at LSU Health ... head and neck cancer has risen at sites associated ... increase among middle-aged white men. At the same time, ...
... developed a new method to detect proteins associated with longevity, ... longer than others. The team looked at the genome ... evolve in connection with the longevity of a species. ... damage, evolves and mutates in a non-random way in species ...
... This press release is available in German . ... a complex process during which different signalling proteins interact with ... VEGF and the Notch signalling pathway both play important roles ... its receptor, VEGFR2, while the Notch signalling pathway acts like ...
Cached Biology News:LSUHSC research finds HPV-related head & neck cancers rising, highest in middle-aged white men 2Study suggests why some animals live longer 2Culprit behind unchecked angiogenesis identified 2
... Radiochemical Purity is >95%\nNEN Radiolabeled Ligands\n\nReceptor-related ... continual availability of new radiolabeled ligands selected ... offers a wide range of products and ... including over 400 state-of-the-art radioligands. If you ...
Request Info...
... 3.1.21.1) is a nonspecific endonuclease that degrades ... by hydrolyzing phosphodiester linkages, producing mono and ... group. Ambion's RNase-free DNase I is of ... to degrade DNA in the presence of ...
Rabbit polyclonal antibody to Neuromedin U Receptor 1 (GPR66)...
Biology Products: